Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LB3Z
|
|||
| Former ID |
DIB000085
|
|||
| Drug Name |
ABL 001
|
|||
| Indication | Chronic myeloid leukaemia [ICD-11: 2A20; ICD-10: C92.7] | Phase 3 | [1] | |
| Promyelocytic leukaemia [ICD-11: 2A82.1; ICD-10: C91.3] | Phase 2 | [1] | ||
| leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [2] | ||
| Company |
Novartis pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040192) | |||
| REF 3 | ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.